Two conditions that feed each other — and why treating one may help manage the other.
Most people think of sleep apnea as a breathing problem and type 2 diabetes as a blood sugar problem. They’re managed by different specialists, tracked by different labs, and treated by different tools. What the research has made increasingly clear, though, is that these two conditions are deeply connected — and understanding that connection changes how both should be approached.
The overlap isn’t incidental. People with type 2 diabetes have significantly higher rates of obstructive sleep apnea (OSA) than the general population, and people with untreated OSA show measurable disruptions in insulin sensitivity and glucose regulation. The question isn’t whether the relationship exists — it’s whether clinicians are acting on it.
For patients managing blood sugar, and for the healthcare providers treating them, sleep-disordered breathing deserves a seat at the table alongside diet, medication, and exercise.
How common is sleep apnea in people with type 2 diabetes?
Far more common than most patients realize. The prevalence of OSA in patients with type 2 diabetes is estimated at approximately 55%, with some studies placing it between 24% and 86% depending on the population studied — and OSA affects more than 60% of hospitalized patients with T2DM.
A 2022 research review estimated that more than half of people with type 2 diabetes have OSA, making it one of the most common but least screened comorbidities in that population.
Despite these numbers, sleep apnea screening is not a standard part of most diabetes management protocols. The result is a large segment of patients whose OSA goes unrecognized while their glycemic control continues to suffer from a cause that’s never addressed.
Why does sleep apnea disrupt blood sugar in the first place?
The mechanism isn’t a single pathway — it’s several, running simultaneously.
When breathing stops repeatedly during sleep, oxygen levels drop and the body registers this as a physiological threat. The stressors of OSA — intermittent hypoxia and sleep fragmentation — activate the sympathetic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis. Healthy individuals exposed to intermittent hypoxia or sleep fragmentation became glucose intolerant in association with increased sympathetic nervous system activity.
Cortisol, the body’s primary stress hormone, rises in response to these nocturnal arousals. Elevated cortisol drives gluconeogenesis — the liver releasing glucose into the bloodstream — at a time when the body should be in a metabolic resting state. The result is higher fasting blood glucose and greater day-to-day glycemic variability, even in people whose daytime habits haven’t changed.
Greater OSA severity corresponds to more marked disturbances in both glucose and lipid metabolism, suggesting a dose-response relationship: the more disrupted the breathing, the more disrupted the metabolic picture.
Does OSA actually cause insulin resistance, or do they just tend to occur together?
Both happen, and the relationship runs in both directions.
OSA produces insulin resistance through the mechanisms described above. At the same time, obesity — which is a major risk factor for both conditions — creates anatomical and hormonal changes that worsen airway collapsibility during sleep. This creates a feedback loop where each condition reinforces the other.
The Sleep Heart Health Study found a 1.44 odds ratio for abnormal glucose tolerance among patients with an apnea-hypopnea index (AHI) of 15 or higher compared to those with lower AHI levels — an association that held even after controlling for obesity and other confounders.
What this means practically: treating sleep apnea doesn’t eliminate the need for diabetes management, but it addresses a driver of insulin resistance that medication alone cannot reach. The two need to be managed together.
What does the A1C picture look like when sleep apnea is treated?
The CPAP evidence on A1C is meaningful, though the effect size is modest and somewhat dependent on adherence. A 2023 systematic review and meta-analysis of 11 randomized controlled trials including 964 patients found that CPAP treatment led to a significant reduction in HbA1c (mean difference −0.24%) compared to inactive control groups, with the amount of improvement associated with hours of CPAP usage.
A 0.24% reduction may sound small, but for patients already using multiple glycemic agents and still struggling to hit target A1C, it represents a meaningful clinical contribution — and one that comes from addressing a root cause rather than adding another medication.
A study using continuous glucose monitoring in patients with both T2DM and OSA found that CPAP treatment significantly improved blood glucose levels and glucose stability, with measurable reductions in mean daily glucose differences and improvements in time-in-range metrics.
What about patients who can’t tolerate CPAP?
CPAP is effective, but adherence is a persistent challenge. Mask discomfort, claustrophobia, noise, and dry mouth lead many patients to abandon it within the first weeks of use.
Oral appliance therapy — specifically custom mandibular advancement devices (MADs) — represents a well-supported alternative, particularly for mild-to-moderate OSA. Mandibular advancement devices offer a less invasive alternative to CPAP with better adherence, especially for patients with mild to moderate OSA.
A prospective study of patients with mild-to-moderate OSA found that MAD treatment over one year improved arterial stiffness, glucose metabolism, and insulin resistance — a finding that makes oral appliance therapy directly relevant to the metabolic picture, not just the sleep picture.
For patients who find CPAP unworkable, a custom oral appliance fitted by a trained dental sleep provider offers a path to consistent, nightly treatment. Consistency is what drives metabolic benefit.
Are there signs that a diabetes patient may have undiagnosed sleep apnea?
Yes — and several of them are easy to miss or attribute to diabetes itself.
Patients managing blood sugar already expect fatigue, brain fog, and disrupted sleep. That overlap is part of why OSA goes undetected in this population. A few patterns worth noting:
– Blood sugar that’s difficult to stabilize despite good dietary and medication compliance
– Elevated fasting glucose that doesn’t respond predictably to treatment
– Morning headaches
– Unrefreshing sleep or insomnia
– Loud or irregular snoring reported by a partner
– Excessive daytime sleepiness not explained by sleep duration
None of these individually confirm OSA, but their presence — especially in a patient whose diabetes management has plateaued — warrants a sleep apnea screening conversation.
Is this relevant for dental providers specifically?
Significantly so. Dentists are positioned to screen for sleep-disordered breathing at routine appointments — a setting where patients are already seated in a chair with an open mouth.
Anatomical indicators of OSA risk (crowded airway, enlarged tongue, scalloping, narrow arch, retrognathia) are visible during examination. Patients who mention fatigue, morning headaches, or acid reflux — all associated with OSA — may be sharing relevant clinical information without knowing its significance.
For dental professionals who have trained in sleep medicine, the ability to provide custom oral appliance therapy creates a direct link between the dental chair and metabolic health outcomes. The dentist who identifies and helps treat a diabetic patient’s undiagnosed OSA is doing something that has real downstream impact on A1C, cardiovascular risk, and quality of life.
What should patients ask their care team?
The most useful question is also the most direct: “Could sleep apnea be affecting my blood sugar?”
Most people with type 2 diabetes have never been asked about their sleep quality in a clinical context. Bringing it up opens a conversation that can lead to home sleep testing — a straightforward, non-invasive evaluation — and from there, to treatment options tailored to the patient’s anatomy, preferences, and compliance history.
What to Do With This Information
If you have type 2 diabetes and haven’t been evaluated for sleep apnea, that’s worth changing. The research connecting these two conditions is substantial — and the tools to diagnose and treat OSA have never been more accessible.
A trained dental sleep provider can screen for sleep apnea risk, coordinate home sleep testing, and fit a custom oral appliance if indicated. Request a sleep apnea evaluation from a dental sleep medicine provider — it’s one of the few steps in diabetes management that targets a metabolic driver most protocols don’t address.
